Chemokines as adjuvants of immune response
US7217700B2 · kind B2 · utility
1Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 24, 2001 |
| Grant date | May 15, 2007 |
| Priority date | — |
| Expiry date | Jan 24, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55522
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer and autoimmune disease, by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dentritic cells to the site of antigen delivery. An increase number of dendritic at the site of antigen delivery means more antigen uptake and a modified immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.